LAG3 and esophageal squamous cell carcinoma: Conduct prospective multicenter studies investigating to combination anti-LAG3 immunotherapy for locally advanced ESCC and expanded multi-institutional cohorts and external datasets are required for validation of current findings, to learn more about specifically evaluate of LAG3's potential as a patient stratification biomarker and its therapeutic target specificity in ESCC immunotherapy.